DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Randomized Trial of Rectal Indomethacin and Papillary Spray of Epinephrine Versus Rectal Indomethacin to Prevent Post-ERCP Pancreatitis in High Risk Patients

Information source: Johns Hopkins University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Post-ERCP Acute Pancreatitis

Intervention: Rectal Indomethacin (Drug); Epinephrine (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Johns Hopkins University

Official(s) and/or principal investigator(s):
Vikesh K Singh, M.D., M.Sc., Principal Investigator, Affiliation: Johns Hopkins University

Overall contact:
Ayesha Kamal, M.B.B.S, Phone: 4438050487, Email: akamal3@jhmi.edu

Summary

This research is being done to see if using a combination of rectal indomethacin and epinephrine spray during endoscopy, can prevent pancreatitis that may occur after ERCP (a type of gastrointestinal endoscopy).

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Primary outcome: Incidence of post-ERCP pancreatitis

Secondary outcome: Severity of post-ERCP pancreatitis

Detailed description: Background: Post-ERCP pancreatitis (PEP) is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP) with an estimated incidence of 3-7% among average

risk patients and 15-20% among patients at high risk for developing PEP. Around 500,000 -

700,000 ERCPs are performed annually in U. S. Even with a modest incidence of 5%, PEP results in approximately $150 million in healthcare costs in the US alone. A recent landmark controlled trial demonstrated the superiority of rectal nonsteroidal

antiinflammatory drug - NSAIDs (indomethacin) over placebo in preventing PEP among patients

at high risk for PEP. Also, epinephrine sprayed on the major duodenal papilla was shown to reduce the incidence of PEP in multiple studies. Our group performed a network meta-analysis (NMA) which simultaneously compared 16 drugs evaluated in 99 randomized controlled trials with 25,313 patients, to determine their relative efficacy using direct and indirect comparisons. Interestingly, the NMA ranked epinephrine as the best performing drug, followed by rectal NSAIDs and nafamostat. Indomethacin acts on pancreatic inflammation while epinephrine sprayed on duodenal papilla keeps the pancreatic duct open by reducing papillary edema. The use of these drugs in combination may potentially synergistically reduce or further reduce the incidence of PEP. Hypothesis: A combination of papillary spray of epinephrine and rectal indomethacin is superior to the use of rectal indomethacin alone, for PEP prophylaxis among patients at high risk for PEP. Sample size justification: Based on the information from earlier controlled trials, we assume that PEP incidence will be 10% in the rectal NSAID arm (Group A) and it will be reduced to 5% by the additional use of papillary spray of epinephrine (Group B). Therefore, a total of 474 patients in each arm, or 948 patients in total, will be required to see a 50% difference between the groups with a power of 0. 8 and two sided alpha of 0. 05. Recruitment and Consenting: Patients scheduled to undergo ERCP will be screened for patient based inclusion / exclusion criteria and will be consented, in the private waiting area of the endoscopy units. Randomization procedures and delivery of drugs: During ERCP performed according to standard clinical care, if the endoscopist determines that the patient meets the criteria for 'high-risk', the study coordinator will randomize the patient to either group A or B in a 1: 1 fashion using a web-based central randomization system. Randomization will be stratified by each center and a randomly varying block size will be used. The patients will be

randomized to either Group A - Patients will receive 20 ml of normal saline sprayed on the

duodenal papilla and surrounding regions of edema, over a period of 1 minute using any ERCP cannulation catheter, at the end of procedure, just before the withdrawal of endoscope;

followed by 100 mg of rectal indomethacin OR Group B - Patients will receive 20 ml of 0. 02%

epinephrine sprayed on the duodenal papilla and surrounding regions of edema, over a period of 1 minute using any ERCP cannulation catheter, at the end of procedure, just before the withdrawal of endoscope; followed by 100 mg of rectal indomethacin. Statistical Plan: For the statistical analysis of primary end point, the difference in proportion of PEP among the two groups will be calculated by stratifying the site and by combining patients from all sites, as separate analyses. A two sided p-value of <0. 05 will be considered statistically significant. The severity of PEP, mortality and other complications related to PEP will also be compared among the two groups. The data on the risk factors of PEP, incidence of PEP will be used for the development of PEP risk Data and safety monitoring board (DSMB) charter: An Independent DSMB, clinical trial monitor (safety officer) will be formed consisting of five endoscopists from India and U. S., with expertise in biostatistics and clinical trial methodology. DSMB will review study related documentation including and not limited to, protocol, standard operating procedures, consent form, data entry forms; monitor study performance, will ensure adherence to good clinical practice guidelines and regulatory requirements; and will make appropriate recommendations to the investigators. All adverse events, will be reported to the safety officer by the study coordinators at each center. Blinded interim analysis will be performed at 33% and 66% of the sample size. If the PEP incidence or complication rate is >25% in any of the treatment groups, DSMB will break randomization code and will terminate the study. During interim analysis, if a statistically significant difference is found between the two groups (p<0. 001), the study will be terminated for ethical considerations.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Major inclusion criteria (If patients meet at least 1 of the criteria):

1. History of PEP 2. Pancreatic sphincterotomy 3. Pre-cut sphincterotomy 4. Difficult cannulation (>5 attempts / 10 minutes to cannulate) 5. Failed cannulation 6. Pneumatic dilation of an intact sphincter 7. Sphincter of Oddi dysfunction of Type I or Type II

- Minor inclusion criteria (If patients meet at least 2 of the criteria):

1. Age < 50 & Female gender 2. History of acute pancreatitis (at least 2 episodes) 3. >/= 3 pancreatic injections (with at least 1 injection in tail) 4. Pancreatic acinarization 5. Pancreatic Brush Cytology Exclusion Criteria: 1. Unwillingness or inability to consent for the study 2. Age < 18 years 3. Intrauterine pregnancy 4. Breastfeeding mother 5. Standard contraindications to ERCP 6. Allergy / hypersensitivity to aspirin or NSAIDs or epinephrine 7. Chronic renal disease (Cr > 1. 4) 8. Active or recent (within 4 weeks) gastrointestinal hemorrhage 9. Acute pancreatitis (lipase peak) within 72 hours 10. Known chronic calcific pancreatitis 11. Pancreatic head mass 12. Receiving pancreatic duct stent placement for any indication 13. Procedure performed on major papilla/ventral pancreatic duct in patients with pancreas divisum 14. ERCP for pancreatic/biliary stent removal or exchange without anticipated pancreatogram 15. Subject with prior biliary sphincterotomy now scheduled for repeat biliary therapy without anticipated pancreatogram 16. Anticipated inability to follow protocol 17. Sphincter of Oddi dysfunction of Type III

Locations and Contacts

Ayesha Kamal, M.B.B.S, Phone: 4438050487, Email: akamal3@jhmi.edu

Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India; Recruiting
Rakesh Kochhar, M.D., D.M.
Rakesh Kochhar, M.D., D.M., Principal Investigator

Asian Institute of gastroenterology, Hyderabad, Andhra Pradesh 500082, India; Recruiting
Nageshwar Reddy Duvvuru
Rupjyoti Talukdar
Nageshwar R Duvvuru, M.D., D.M, Principal Investigator
Rupjyoti Talukdar, M.D., D.N.B, Principal Investigator

Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, United States; Recruiting
Ayesha Kamal, M.B.B.S, Phone: 443-805-0487, Email: akamal3@jhmi.edu
Vikesh k singh, M.D., M.Sc, Principal Investigator
Venkata S Akshintala, M.D., Sub-Investigator

Apollo Gleneagles Hospitals, Kolkata, West Bengal 700054, India; Recruiting
Mahesh K Goenka, M.D., D.M.
Mahesh K Goenka, M.D., D.M., Principal Investigator

Additional Information

Related publications:

Elmunzer BJ, Scheiman JM, Lehman GA, Chak A, Mosler P, Higgins PD, Hayward RA, Romagnuolo J, Elta GH, Sherman S, Waljee AK, Repaka A, Atkinson MR, Cote GA, Kwon RS, McHenry L, Piraka CR, Wamsteker EJ, Watkins JL, Korsnes SJ, Schmidt SE, Turner SM, Nicholson S, Fogel EL; U.S. Cooperative for Outcomes Research in Endoscopy (USCORE). A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med. 2012 Apr 12;366(15):1414-22. doi: 10.1056/NEJMoa1111103.

Akshintala VS, Hutfless SM, Colantuoni E, Kim KJ, Khashab MA, Li T, Elmunzer BJ, Puhan MA, Sinha A, Kamal A, Lennon AM, Okolo PI, Palakurthy MK, Kalloo AN, Singh VK. Systematic review with network meta-analysis: pharmacological prophylaxis against post-ERCP pancreatitis. Aliment Pharmacol Ther. 2013 Dec;38(11-12):1325-37. doi: 10.1111/apt.12534. Epub 2013 Oct 20. Review.

Xu LH, Qian JB, Gu LG, Qiu JW, Ge ZM, Lu F, Wang YM, Li YM, Lu HS. Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis by epinephrine sprayed on the papilla. J Gastroenterol Hepatol. 2011 Jul;26(7):1139-44. doi: 10.1111/j.1440-1746.2011.06718.x.

Matsushita M, Takakuwa H, Shimeno N, Uchida K, Nishio A, Okazaki K. Epinephrine sprayed on the papilla for prevention of post-ERCP pancreatitis. J Gastroenterol. 2009;44(1):71-5. doi: 10.1007/s00535-008-2272-8. Epub 2009 Jan 22.

Starting date: August 2014
Last updated: May 5, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017